Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DOPD
- Ownership
- Private
- Development stage
- Other
01
Overview
DOPD is an early-stage biotechnology company focused on developing novel therapeutic interventions for neurological and metabolic disorders. The company primarily targets the DOPA decarboxylase (DDC) enzyme pathway to address conditions such as aromatic L-amino acid decarboxylase (AADC) deficiency and Parkinson's disease. By leveraging advanced gene therapy and small molecule approaches, DOPD aims to restore enzymatic function and improve neurotransmitter regulation in affected patients. The company's research is currently in the pre-clinical phase, with a focus on optimizing delivery mechanisms and establishing proof-of-concept in animal models.
- Therapeutic areas
- Rare DiseasesNeurology
- Modalities
- Small moleculeGene therapyBiologic
- Industry
- Biotech
Beyond the preview
Go deeper on DOPD.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DOPD.